Information Provided By: 
Fly News Breaks for August 6, 2019
HRTX
Aug 6, 2019 | 07:57 EDT
Heron Therapeutics is trading near its 52-week low and the timeline for resolution of HTX-011's Complete Response Letter remains the key focus for investors, Jefferies analyst Biren Amin tells investors in a research note. By the analyst's estimate, a re-filing could happen in late September or early October, tracking towards a Q2 of 2020 launch. Heron shares could be back to the low $20s with a near-term re-filing announcement, says Amin. He keeps a Buy rating on the name with a $37 price target.
News For HRTX From the Last 2 Days
HRTX
Apr 26, 2024 | 10:52 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Heron Therapeutics (HRTX),... To see the rest of the story go to thefly.com. See Story Here
HRTX
Apr 25, 2024 | 10:38 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
